Small molecules that targeting p53 Y220C protein: mechanisms, structures, and clinical advances in anti-tumor therapy
Molecular Diversity · 2025
DOI: 10.1007/s11030-024-11045-x ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Diversity, 2025. Verfasst von Jinglei Xu und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, People's Republic of China. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Antineoplastic Agents, Small Molecule Libraries, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jiangsu Province Natural Science Funds, "Double First-Class" Young Talents Research and Innovation Team Project.
Abstract (Originalsprache)
The p53 protein is regarded as the "Guardian of the Genome," but its mutation is tumor progression and present in more than half of malignant tumors. The pro-metastatic property of mutant p53 makes a strong argument for targeting mutant p53 with new therapeutic strategies. However, mutant p53 was considered as a challenging target for drug discovery due to the lack of small molecular binding pockets. Among them, mutant p53 Y220C creates a narrow crevice since the side chains dynamics on protein surface, which is suitable for designing small molecules to occupy the cavity and recovery the tumor suppressing function. Here, we describe the mechanism of p53 related signal pathway and how p53 Y220C regulate the tumorigenesis. We review the two types of p53 Y220C modulators including restoring the conformation of mutant p53 Y220C protein to wild-type p53 protein and recruiting histone acetyltransferase p300/CBP to acetylate p53 Y220C thus enables p53 Y220C dependent upregulation of apoptotic genes and downregulation of DNA damage response pathways. We also report clinical advances and challenges of these molecules in p53 Y220C medicated tumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, People's Republic of China.
- School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, People's Republic of China. lutao@cpu.edu.cn.
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, People's Republic of China. lutao@cpu.edu.cn.
- School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, People's Republic of China. lihongmei@cpu.edu.cn.
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, People's Republic of China. lihongmei@cpu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Jiangsu Province Natural Science Funds
- "Double First-Class" Young Talents Research and Innovation Team Project
- “Double First-Class” Young Talents Research and Innovation Team Project
Zitieren
APA
Xu, J., Yuan, J., Wang, W., Zhu, X., Li, J., Ma, Y., Liu, S., Feng, J., Chen, Y., Lu, T., & Li, H. (2025). Small molecules that targeting p53 Y220C protein: mechanisms, structures, and clinical advances in anti-tumor therapy. Molecular Diversity. https://doi.org/10.1007/s11030-024-11045-x
Vancouver
Xu J, Yuan J, Wang W, Zhu X, Li J, Ma Y, et al. Small molecules that targeting p53 Y220C protein: mechanisms, structures, and clinical advances in anti-tumor therapy. Molecular Diversity. 2025. doi:10.1007/s11030-024-11045-x
BibTeX
@article{Xu2025,
author = {Xu, Jinglei and Yuan, Jiahao and Wang, Wenxin and Zhu, Xiaoning and Li, Jialong and Ma, Yule and Liu, Shaojie and Feng, Jie and Chen, Yadong and Lu, Tao and Li, Hongmei},
title = {Small molecules that targeting p53 Y220C protein: mechanisms, structures, and clinical advances in anti-tumor therapy},
journal = {Molecular Diversity},
year = {2025},
doi = {10.1007/s11030-024-11045-x}
}
EUVIMED